[go: up one dir, main page]

SV2018005687A - Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer - Google Patents

Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer

Info

Publication number
SV2018005687A
SV2018005687A SV2018005687A SV2018005687A SV2018005687A SV 2018005687 A SV2018005687 A SV 2018005687A SV 2018005687 A SV2018005687 A SV 2018005687A SV 2018005687 A SV2018005687 A SV 2018005687A SV 2018005687 A SV2018005687 A SV 2018005687A
Authority
SV
El Salvador
Prior art keywords
dihydroimidazopirazinona
cancer treatment
derivatives used
cancer
description
Prior art date
Application number
SV2018005687A
Other languages
English (en)
Inventor
Richard Andrew Ward
Cliford David Jones
Mark Andrew Graham
Steven Swalow
Andrew Hornby Dobson
James Francis Mccabe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SV2018005687A publication Critical patent/SV2018005687A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA (I) (VER FORMULA) O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE R1 , R2 Y R3 TIENEN CUALQUIERA DE LOS SIGNIFICADOS DEFINIDOS ANTERIORMENTE EN EL PRESENTE DOCUMENTO EN LA DESCRIPCIÓN; PROCESOS PARA SU PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN EL TRATAMIENTO DEL CÁNCER.
SV2018005687A 2015-11-09 2018-05-07 Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer SV2018005687A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252726P 2015-11-09 2015-11-09
US201662401351P 2016-09-29 2016-09-29

Publications (1)

Publication Number Publication Date
SV2018005687A true SV2018005687A (es) 2018-07-20

Family

ID=57241113

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005687A SV2018005687A (es) 2015-11-09 2018-05-07 Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer

Country Status (35)

Country Link
US (2) US9902731B2 (es)
EP (1) EP3374359B1 (es)
JP (1) JP6877423B2 (es)
KR (1) KR20180074788A (es)
CN (1) CN108349983B (es)
AU (1) AU2016351813B2 (es)
BR (1) BR112018008397B1 (es)
CA (1) CA3003549A1 (es)
CL (1) CL2018001226A1 (es)
CO (1) CO2018004857A2 (es)
CR (1) CR20180316A (es)
CY (1) CY1123627T1 (es)
DK (1) DK3374359T3 (es)
EA (1) EA038028B1 (es)
ES (1) ES2780650T3 (es)
HR (1) HRP20200342T1 (es)
IL (1) IL258953A (es)
LT (1) LT3374359T (es)
ME (1) ME03770B (es)
MX (1) MX376639B (es)
MY (1) MY197626A (es)
NI (1) NI201800058A (es)
PE (1) PE20181288A1 (es)
PH (1) PH12018500987A1 (es)
PL (1) PL3374359T3 (es)
PT (1) PT3374359T (es)
RS (1) RS60155B1 (es)
SG (1) SG11201803066VA (es)
SI (1) SI3374359T1 (es)
SM (1) SMT202000152T1 (es)
SV (1) SV2018005687A (es)
TN (1) TN2018000119A1 (es)
TW (1) TWI730012B (es)
WO (1) WO2017080979A1 (es)
ZA (1) ZA201803742B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3365334T1 (sl) 2015-10-21 2024-10-30 Otsuka Pharmaceutical Co., Ltd. Spojine benzolaktama kot zaviralci protein kinaze
CA3003549A1 (en) * 2015-11-09 2017-05-18 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
CN110577543B (zh) * 2018-10-10 2022-07-08 深圳市塔吉瑞生物医药有限公司 一种二氢咪唑并吡嗪酮化合物及包含该化合物的组合物及其用途
EP3950693A4 (en) 2019-03-28 2022-09-07 Jiangsu Hengrui Medicine Co., Ltd. THIENOHETEROCYCLIC DERIVATIVE, METHOD FOR PREPARING IT AND ITS MEDICAL USE
EP3978498A1 (en) 2019-05-24 2022-04-06 Jiangsu Hengrui Medicine Co., Ltd. Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines
US20220315597A1 (en) * 2019-06-06 2022-10-06 Hutchison Medipharma Limited Tricyclic compounds and their use
AR120685A1 (es) * 2019-12-05 2022-03-09 Astrazeneca Ab Proceso e intermediarios para la producción de la fórmula (1)
EP4071155A4 (en) * 2019-12-06 2024-01-17 D3 Bio (Wuxi) Co., Ltd. THIAZOLOLACTAM COMPOUND USED AS ERK INHIBITOR AND USE THEREOF
US20230331731A1 (en) 2020-09-29 2023-10-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal form of pyrrolo heterocyclic derivative and preparation method therefor
AR126166A1 (es) * 2021-06-18 2023-09-27 Antengene Discovery Ltd Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos
WO2022268065A1 (en) * 2021-06-22 2022-12-29 Fochon Biosciences, Ltd. Compounds as erk inhibitors
EP4378478A4 (en) 2021-07-27 2025-11-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
WO2023081859A1 (en) 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Triazine amino derivatives for treating sca3
US20250340571A1 (en) 2022-04-27 2025-11-06 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2023220439A1 (en) 2022-05-12 2023-11-16 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2024006971A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
AU2003278377A1 (en) * 2002-11-06 2004-06-07 Merck Sharp And Dohme Limited Imidazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
JP5178738B2 (ja) * 2006-12-20 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション 新規なｊｎｋ阻害剤
WO2012085038A1 (en) * 2010-12-22 2012-06-28 Janssen Pharmaceutica Nv 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
US9643970B2 (en) * 2011-10-10 2017-05-09 H. Lundbeck A/S Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors
JP2013166727A (ja) * 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
MX354675B (es) 2012-03-01 2018-03-15 Array Biopharma Inc Inhibidores de serina/treonina cinasa.
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
JP6449293B2 (ja) 2013-12-06 2019-01-09 ジェネンテック， インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
CA2934709C (en) 2013-12-30 2022-08-30 Array Biopharma Inc. Serine/threonine kinase inhibitors
BR112016015235A2 (pt) 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
AR099989A1 (es) 2014-04-09 2016-08-31 Genentech Inc Proceso de preparación de (s)-1-(1-(4-cloro-3-fluorofenil)-2-hidroxietil)-4-(2-((1-metil-1h-pirazol-5-il)amino)pirimidin-4-il)-2(1h)-ona y sus sales
US10412619B2 (en) * 2014-11-14 2019-09-10 Qualcomm Incorporated Buffer status report for eDCS
WO2016162325A1 (en) * 2015-04-07 2016-10-13 Astrazeneca Ab Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors
WO2016192063A1 (en) 2015-06-03 2016-12-08 Changzhou Jiekai Pharmatech Co. Ltd Heterocyclic compounds as erk inhibitors
WO2016192064A1 (en) 2015-06-03 2016-12-08 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
CA3003549A1 (en) * 2015-11-09 2017-05-18 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer

Also Published As

Publication number Publication date
MY197626A (en) 2023-06-29
EP3374359A1 (en) 2018-09-19
WO2017080979A1 (en) 2017-05-18
LT3374359T (lt) 2020-03-25
TW201728586A (zh) 2017-08-16
BR112018008397B1 (pt) 2023-12-12
SG11201803066VA (en) 2018-05-30
TN2018000119A1 (en) 2019-10-04
BR112018008397A2 (pt) 2018-10-23
AU2016351813A1 (en) 2018-06-21
ME03770B (me) 2021-04-20
PT3374359T (pt) 2020-03-27
SI3374359T1 (sl) 2020-04-30
CY1123627T1 (el) 2022-03-24
HK1256283A1 (en) 2019-09-20
PE20181288A1 (es) 2018-08-07
KR20180074788A (ko) 2018-07-03
ZA201803742B (en) 2020-08-26
EA201891063A1 (ru) 2018-12-28
IL258953A (en) 2018-06-28
JP2019503337A (ja) 2019-02-07
SMT202000152T1 (it) 2020-05-08
CA3003549A1 (en) 2017-05-18
PH12018500987A1 (en) 2019-01-28
DK3374359T3 (da) 2020-03-30
CR20180316A (es) 2018-10-05
MX376639B (es) 2025-03-07
CO2018004857A2 (es) 2018-07-19
PL3374359T3 (pl) 2020-06-29
US10202391B2 (en) 2019-02-12
RS60155B1 (sr) 2020-05-29
TWI730012B (zh) 2021-06-11
US20170204100A1 (en) 2017-07-20
CN108349983A (zh) 2018-07-31
US20180237443A1 (en) 2018-08-23
CL2018001226A1 (es) 2018-10-05
JP6877423B2 (ja) 2021-05-26
US9902731B2 (en) 2018-02-27
AU2016351813B2 (en) 2019-05-30
ES2780650T3 (es) 2020-08-26
CN108349983B (zh) 2021-02-26
EA038028B1 (ru) 2021-06-24
EP3374359B1 (en) 2020-01-08
HRP20200342T1 (hr) 2020-06-12
NI201800058A (es) 2018-10-18
MX2018005725A (es) 2018-08-14

Similar Documents

Publication Publication Date Title
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
DOP2015000274A (es) Compuestos químicos
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
CL2019001993A1 (es) Inhibidores selectivos de jak1.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
ECSP15014941A (es) Compuestos antivíricos para el vsr
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
NI201500096A (es) Compuesto químicos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
ECSP18056196A (es) Derivados de indano
UY36958A (es) Compuestos para administración intracelular
UY36464A (es) Compuestos de quinazolina
BR112016028017A2 (pt) Inibidor de quinase alk e método de preparação e usos do mesmo